·PIB·15 marks·250–350 words

Bridging the research-policy gap is central to evidence-based health governance in India. Discuss in the context of recent DHR initiatives.

New · District CollectorCan you hold the district for 72 hours?Floods, a heatwave, an outbreak, a grievance queue. Take the decisions, see the consequences.Play →
In this answer
  1. Why bridging the gap matters
  2. Recent DHR initiatives bridging the gap
  3. Persisting gaps

Evidence-based health governance means that policies, purchases and outbreak responses rest on tested data, not on guesswork. In India, much health research has stayed in journals and laboratories. Recent initiatives of the Department of Health Research (DHR) show a clear shift from "publish" to "apply". Some structural gaps still remain.

Why bridging the gap matters

  • Scarce funds: public health spending is only about 1.8% of GDP, against a recommended 2.5% [2]. Every rupee therefore needs evidence behind it.
  • Preparedness: COVID-19 showed that late detection of an outbreak costs both lives and the economy.

Recent DHR initiatives bridging the gap

  • Research to Action Vertical (2026): turns research evidence into decision-ready products for policy and health programmes [1].
  • Health Technology Assessment: the HTA Technologies Compendium and the HTA Costing Database, released at ISHTA 2025, support value-for-money purchasing [3].
  • Syndromic surveillance under the VRDL Scheme: covers 70 VRDLs and IRDLs and flags outbreaks from symptom patterns before lab confirmation [1].
  • AMR Annual Report and SOPs: bring national evidence together and standardise lab methods, so data can be compared across institutions [1].
  • Lab to market: under Medical Innovations Patent Mitra, ICMR crossed 100 technology-transfer deals in less than two years [1].
Research → Research to Action Vertical / HTA → Policy & purchase → Programme data → Research

Evidence-to-policy feedback loop

Persisting gaps

  • Capacity: 16% of ICMR's sanctioned scientist posts were vacant in 2023 [2][4]. New tasks are being added to an already stretched workforce.
  • Funding: the Parliamentary Standing Committee on Health flagged a persistent gap between the funds DHR sought and the funds it received. It recommended that health research get 5% of the Ministry's spending [4].
  • Fragmented data: ICMR's AMRSN and NCDC's NARS-Net run as two parallel AMR networks [5]. VRDL warning signals must still reach the district teams that work under IDSP.
  • Opaque outcomes: deal counts do not show whether products reached patients, or at what price.

Together, DHR's initiatives build a pipeline from evidence to decision. To make that pipeline work, India should:

  • link VRDL signals with IHIP;
  • merge the two AMR datasets;
  • fill scientist vacancies, as the Standing Committee urged;
  • publish licence outcomes.

These steps would help fulfil the Article 47 duty to improve public health and advance SDG 3, with evidence rather than intuition as the basis of health governance.

Sources

  1. 13rd DHR-ICMR Health Research Excellence Summit, PIB release (Nov 2026)Research to Action Vertical, syndromic surveillance in 70 VRDLs/IRDLs, AMR Annual Report and SOPs, 100 Patent Mitra deals
  2. 2PRS Legislative Research, Demand for Grants 2026-27 Analysis: Health and Family Welfarehealth spending at 1.8% of GDP against 2.5%; 16% of ICMR scientist posts vacant
  3. 3WHO India, "Health Technology Assessment key to achieving health for all" (March 2025)HTA Technologies Compendium and Costing Database released at ISHTA 2025
  4. 4PRS Legislative Research, Demand for Grants 2025-26 Analysis: Health and Family WelfareStanding Committee findings on scientist vacancies, the funding gap and the 5% recommendation
  5. 5PIB, Measures taken to address challenges posed by anti-microbial resistance (AMR) in IndiaICMR's AMRSN and NCDC's NARS-Net as parallel networks

More from this note